GenSight Biologics S.A. (GSGTF)
| Previous close | 0.4500 |
| Open | 0.4800 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 0.4500 - 0.4500 |
| 52-week range | 0.0003 - 3.1000 |
| Volume | |
| Avg. volume | 12 |
| Market cap | 35.115M |
| Beta (5Y monthly) | 2.14 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.6700 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireGenSight Biologics Reports Cash Position as of March 31, 2024, and Provides Business Update
PARIS, April 04, 2024--Regulatory News: GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position as of March 31, 2024 and provided a business update.
Business WireGenSight Biologics Announces its 2024 Financial Calendar
PARIS, April 04, 2024--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced its financial calendar for 2024.
Business WireGenSight Biologics Reports Full Year 2023 Consolidated Financial Results
PARIS, March 22, 2024--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its full year 2023 consolidated financial results, as approved by the Board of Directors on March 21, 2024. Audit procedures on the Company’s 2023 consolidated financial statements were completed by the C
